Antihyperlipidemic effects of red ginseng, crataegii fructus and their main constituents ginsenoside Rg3 and ursolic acid in mice

Biomolecules and Therapeutics

Volumn 16, Issue 4, 2008, Pages 364-369

  Min, Sung Won ^a   Jung, Sang Hyun ^a   Cho, Ki Ho ^a   Kim, Dong Hyun ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Crataegus pinnatifida; Ginsenoside Rg3; HMG CoA reductase; Hyperlipidemia; Pancreatic lipase; Red ginseng; Ursolic acid

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; CORN OIL; CRATAEGII FRUCTUS EXTRACT; CRATAEGUS EXTRACT; GINSENG EXTRACT; GINSENOSIDE RG 1; GINSENOSIDE RG 2; GINSENOSIDE RG 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVINOLIN; RED GINSENG EXTRACT; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; TYLOXAPOL; UNCLASSIFIED DRUG; URSOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERLIPIDEMIC ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CRATAEGII FRUCTUS; CRATAEGUS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; EPIDIDYMIS FAT; GINSENG; HERBAL MEDICINE; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID DIET; MALE; MOUSE; NONHUMAN; RAT; RED GINSENG; TRIACYLGLYCEROL BLOOD LEVEL;

CRATAEGUS PINNATIFIDA; MUS; PANAX GINSENG; ZEA MAYS;

EID: 68649127279     PISSN: 19769148     EISSN: None     Source Type: Journal    
DOI: 10.4062/biomolther.2008.16.4.364     Document Type: Article

References (27)

1. Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W. and Fu, P. C.(1974). Enzymatic determination of total serum cholesterol. Clin. Chem. 20, 470-475.
2. Bae, E. A., Han, M. J., Choo, M. K., Park, S. Y. and Kim, D. H.(2002). Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol. Pharm. Bull. 25, 58-63.
3. Ballinger, A. (2000). Orlistat in the treatment of obesity. Expert. Opin. Pharmacother. 1, 841-847 .
4. Birari, R. B. and Bhutani, K. K. (2007). Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discovery Today 12, 879-889.
5. Carey, M. C., Small, D. M. and Bliss, C. M. (1993). Lipid digestion and absorption. Annu. Rev. Physiol. 45, 651-677.
6. Chang, W. T., Dao, J., Shao, Z. H. (2005). Hawthorn: potential roles in cardiovascular disease. Am. J. Chin. Med. 33, 1-10. (Pubitemid 40468298)
7. Davidson, M. H. (2003). Ezetimibe: a novel option for lowering cholesterol. Expert. Rev. Cardiovasc. Ther. 1, 11-21.
8. Duhault, J., Boulanger, M., Beregi, L., Sicot, N., Bouvier, F. (1976). 780 SE: a new type of hypolipemic agent. Atherosclerosis, 23, 63-72.
9. Edwards, P. A., Lemongello, D. and Fogelman, A. M. (1979). Improved methods for the solubilization and assay of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Lipid Res. 20, 40-46. (Pubitemid 9130724)
10. Edwards, P. A., Lemongello, D. and Kane, J. (1980). Properties of purified rat hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and regulation of enzyme activity. J. Biol. Chem. 255, 3715-3725.
11. Endo, A. (1992). The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33, 1569-1582.
12. Espenshade P. J., Hughes A. L. (2007). Regulation of sterol synthesis in eukaryotes. Annu. Rev. Genet. 41, 401-427.
13. Goldstein, J. L., Schrott, H., Hazzard, E., Bierman, E. and Motuski, A. (1973). Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J. Clin. Invest. 52, 1544-1568.
14. Heber, D. (2001). Herbs and atherosclerosis. Curr. Atheroscler. Rep. 3, 93-96.
15. Heller, R. A. and Shrewsburg, M. A. (1976). 3-Hydroxy-3-methylglutaryl coenzyme A reductase from rat liver. Its purification, properties, and immunochemical studies. J. Biol. Chem. 251, 3815-3822.
16. Ia Cour, B., Molgaard, P., Yi, Z. (1995). Traditional Chinese medicine in treatment of hyperlipidaemia. J. Ethnopharmacol. 46, 125-129 (1995). .
17. Inoue, M., Wu C.Z., Dou D.Q., Chen Y.J., Ogihara Y. (1999). Lipoprotein lipase activation by red ginseng saponins in hyperlipidemia model animals. Phytomedicine 6, 257-265. (Pubitemid 129633199)
18. Kim H. Y., Jeong da, M., Jung, H. J., Jung, Y. J., Yokozawa, T. and Choi, J. S. (2008). Hypolipidemic effects of Sophora flavescens and its constituents in poloxamer 407-induced hyperlipidemic and cholesterol-fed rats. Biol. Pharm. Bull. 31, 73-78 .
19. Liu, J. (1995). Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol. 49, 57-68.
20. Meigs, T. E., Roseman, D. S. and Simoni, R. D. (1996). Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J. Biol. Chem. 271, 7916-7922
21. Thomson, A. B., Schoeller, C., Keelan, M., Smith, L. Clandinin M. T. (1993). Lipid absorption: passing through the unstirred layers, brush-border membrane, and beyond. Can. J. Physiol. Pharmacol. 71, 531-555.
22. Thompson Coon J. S. and Ernst E. (2003). Herbs for serum cholesterol reduction: a systematic view. J. Fam. Pract. 52, 468-478
23. Trinh, H. T., Han, S. J., Kim, S. W., Lee, Y. C. and Kim, H. D. (2007). Bifidus fermentation increases hypolipidemic and hypoglycemic effects of red ginseng. J. Microbiol. Biotechnol. 17, 1127-1133.
24. White, L. W. and Rudney, H. (1970). Regulation of 3-hydroxy-3- methylglutarate and mevalonate biosynthesis by rat liver homogenates. Effects of fasting, cholesterol feeding, and triton administration. Biochemistry 9, 2725-2731.
25. Zhou, L., Zuo, Z. and Chow, M. S. (2005). Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol. 45, 1345-1359. (Pubitemid 41643896)
26. Kusama, H., Nishiyama, M. and Ikeda, S. (1988). Pharmacological investigation of bezafibrate, a hypolipidemic agent (1). Effects of bezafibrate on normal and experimental hyperlipidemia in rats. Folia Pharmacol. Jpn. 92, 175-180 (Pubitemid 18207699)
27. Sardesai V.M. and Mannig J.A., The determination of triglycerides in plasma and tissues. Clin. Chem. 14, 156-158.